GENEDRIVE PLC — AGM Information 2018

Dec 31, 2018

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 8270L

Genedrive PLC

31 December 2018

For release: 31 December 2018

genedrive plc ("genedrive" or the "Company")

Result of AGM

genedrive plc (LSE: GDR), the near patient molecular diagnostics company, announces that at the Annual General Meeting, held today, all resolutions proposed were duly passed.

- Ends -

For further details please contact:

genedrive plc	+44 (0)161 989 0245
David Budd: CEO
Matthew Fowler: CFO
Peel Hunt LLP
James Steel	+44 (0)207 418 8900
Oliver Jackson
Stanford Capital Partners Limited	+44 (0)203 815 8880
Patrick Claridge
John Howes
Consilium Strategic Communications	+44 (0)203 709 5700
Chris Gardner	genedrive@consilium-comms.com
Matthew Neal
Laura Thornton

Notes to Editors

About genedrive plc

genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Genedrive® HCV-ID test has received CE-IVD Certification and has been launched in Africa and Asia Pacific. genedrive has distribution agreements with subsidiaries of Sysmex Corporation for the distribution of the Genedrive® platform in the EMEA and SE Asia (ex-India), and with ARKRAY Healthcare pvt Ltd for the distribution of the Genedrive® HCV-ID Kit and Genedrive® platform in India. Further details can be found at: www.genedriveplc.com and www.genedrive.com. The Company also has tests in development for tuberculosis (mTB) and Antibiotic Induced Hearing Loss (AIHL).

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

RAGBBBDDXDXBGIB